new Alzheimer's disease treatment lecanemab should be priced lower than the drug Aduhelm that was developed by the companies.released on Thursday, the Institute for Clinical and Economic Review said a price range of between $8,500 and $20,600 annually for lecanemab would meet some commonly used thresholds for cost effectiveness.
Treatment with lecanemab for patients with Alzheimer's appears to be "promising but inconclusive," ICER said. ICER is not a government agency and has no authority to set prices, but many large health insurers take their reports into account when they negotiate prices. Some manufacturers also take into account the ICER recommendations when they set prices.
Doamne să fie adevărat!
Drink water a lot
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: